MIRA Pharmaceuticals Inc (MIRA) Stock AnalysisMIRAMIRA Pharmaceuticals Inc

MIRA Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of therapeutics for neurologic, neuropsychiatric, and metabolic disorders. The Company's pipeline includes oral drug candidates designed to address significant unmet medical needs in neuropathic pain, inflammatory pain, obesity, addiction, anxiety, and cognitive decline. It holds exclusive license rights in the United States, Canada and Mexico for Ketamir-2 and MIRA-55, two novel drug candidates designed to address unmet medical needs in neuropathic and inflammatory pain, as well as neuropsychiatric and neurocognitive disorders. Its pipeline also includes SKNY-1, a next-generation oral therapy candidate for obesity and smoking cessation. Ketamir-2 is a patent-pending oral ketamine analog evaluated for the treatment of diabetic neuropathy and is in an ongoing Phase I clinical trial. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Mira Pharmaceuticals Inc is not a good buy right now due to its current price of 0.75, which is significantly down 49.66% year-to-date, indicating a downward trend. Additionally, the RSI is at 45.63, suggesting it is neither overbought nor oversold, but the negative momentum is concerning. The company's forward P/E ratio is 0, indicating a lack of earnings growth expectations, and the last earnings report showed an EPS of -0.03, reflecting ongoing losses.